TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21591523

Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Paracervical block
Number of subjects: 64
Study: 19133704

Group type: EXPERIMENTAL
Intervention: Armodafinil (50-400 mg, once daily for up to 14 days)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Armodafinil (50-400 mg)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Armodafinil
Number of subjects: 119
Study: 16886931

Group type: EXPERIMENTAL
Intervention: Migraineurs
Number of subjects: 50

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 50
Study: 16024131

Group type: EXPERIMENTAL
Intervention: IGF-I therapy (20 microg/kg/day with dose escalation to 50-100 microg/kg/day for 4 months)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12538212

Group type: EXPERIMENTAL
Intervention: Epidural block with bupivacaine (EDA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: General anesthesia alone (Control)
Number of subjects: 16
Study: 10215195

Group type: EXPERIMENTAL
Intervention: Leukocyte depletion through the venous bypass circuit
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 7609336

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Number of subjects: 22

Group type: COMPARATOR
Intervention: Compressed air
Number of subjects: 22

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 22
Study: 2792920

Group type: EXPERIMENTAL
Intervention: Oral tinidazole (150 mg X 2) for 7 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral tinidazole (150 mg X 2) for 7 days with partner receiving 500 mg X 2 for 4 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intravaginal tinidazole (500 mg) at bedtime for 2 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intravaginal tinidazole (500 mg) at bedtime for 2 weeks with IUCD
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral tinidazole (150 mg X 2) for 7 days with IUCD
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral tinidazole (150 mg X 2) for 7 days with partner receiving 500 mg X 2 for 4 days and IUCD
Number of subjects: 90
Study: 292537

Group type: EXPERIMENTAL
Intervention: Ambulation on pylon within 24 hours of surgery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ambulation at time of suture removal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Casts applied by physical therapists
Number of subjects: 24

Group type: COMPARATOR
Intervention: Casts applied by prosthetists
Number of subjects: 24

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 24
Study: 29369680

Group type: EXPERIMENTAL
Intervention: Attention manipulation to losses or gains in Experiment 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predecisional attention allocation to outcome and probability information in Experiment 1
Number of subjects: 0
Study: 28592074

Group type: EXPERIMENTAL
Intervention: iASSIST-TKA
Number of subjects: 47

Group type: COMPARATOR
Intervention: PSI-TKA
Number of subjects: 47
Study: 26537937

Group type: EXPERIMENTAL
Intervention: Cocoa flavanol intake (up to 2000 mg/d for 12 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: CF-free control
Number of subjects: 80
Study: 22922327

Group type: EXPERIMENTAL
Intervention: 1kHz IFC
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 2kHz IFC
Number of subjects: 150

Group type: COMPARATOR
Intervention: 8kHz IFC
Number of subjects: 150

Group type: COMPARATOR
Intervention: 10kHz IFC
Number of subjects: 150

Group type: COMPARATOR
Intervention: 4kHz IFC
Number of subjects: 150
Study: 20049578

Group type: EXPERIMENTAL
Intervention: Orogastric (OG) tube with suctioning
Number of subjects: 32

Group type: COMPARATOR
Intervention: No OG tube
Number of subjects: 32
Study: 18476432

Group type: EXPERIMENTAL
Intervention: Qianlie Huazhuo Capsule (QHC)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Qianlie Jiedu Capsule (Control)
Number of subjects: 65
Study: 15982658

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 481

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 481
Study: 12753271

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Calcium carbonate (CC)
Number of subjects: 98
Study: 10540069

Group type: EXPERIMENTAL
Intervention: Target-controlled infusion of propofol and remifentanil (125 microg of remifentanil added to 500 mg of propofol)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Inhalational anaesthesia with sevoflurane and intra-operative alfentanil
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 71
Study: 8712091

Group type: EXPERIMENTAL
Intervention: Bicalutamide (10-100 mg orally daily for 12 weeks)
Number of subjects: 16
Study: 2032862

Group type: EXPERIMENTAL
Intervention: Aluminized body covers
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aluminized head cover
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both head and body aluminized covers
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition (no aluminized covers)
Number of subjects: 60
Study: 7049311

Group type: EXPERIMENTAL
Intervention: Rectal metronidazole twice-daily for 5 days
Number of subjects: 71

Group type: COMPARATOR
Intervention: No further antibacterial treatment
Number of subjects: 71
Study: 31445345

Group type: EXPERIMENTAL
Intervention: Escitalopram 30 mg per day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Escitalopram 20 mg per day plus placebo
Number of subjects: 50
Study: 29911768

Group type: EXPERIMENTAL
Intervention: Single-shot sciatic nerve block (SNB) with 0.25% bupivacaine 25 ml + continuous femoral analgesia (CFA) 0.125% bupivacaine 7 ml/h
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Parenteral parecoxib 40 mg q 12 hours + continuous femoral analgesia (CFA) 0.125% bupivacaine 7 ml/h
Number of subjects: 78

Group type: COMPARATOR
Intervention: Only continuous femoral analgesia (CFA) 0.125% bupivacaine 7 ml/h
Number of subjects: 78
Study: 25982007

Group type: EXPERIMENTAL
Intervention: Reinforcement-Based Treatment (RBT) plus low cost Contingency Management (CM)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Reinforcement-Based Treatment (RBT)
Number of subjects: 262
Study: 24485109

Group type: EXPERIMENTAL
Intervention: Warmed irrigation fluid (36°C)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Room-temperature irrigation fluid
Number of subjects: 72
Study: 22464778

Group type: EXPERIMENTAL
Intervention: Warming kidney prescription treatment
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control (telbivudine monotherapy only)
Number of subjects: 96
Study: 19427806

Group type: EXPERIMENTAL
Intervention: Moving to Opportunity (MTO) housing intervention
Number of subjects: 22
Study: 17289477

Group type: EXPERIMENTAL
Intervention: Remifentanil (1 microg/kg/min)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sufentanil (1 microg/kg for induction, 0.5 microg/kg for skin incision, and then 0.02 microg/kg/min)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 120
Study: 15603013

Group type: EXPERIMENTAL
Intervention: CD-ROM-based multimedia psychoeducational intervention
Number of subjects: 194

Group type: COMPARATOR
Intervention: Printed material
Number of subjects: 194
Study: 11074109

Group type: EXPERIMENTAL
Intervention: Late-night sleep deprivation (LSD)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Early-night sleep deprivation (ESD)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Recovery sleep after LSD
Number of subjects: 9

Group type: COMPARATOR
Intervention: Recovery sleep after ESD
Number of subjects: 9
Study: 9314933

Group type: EXPERIMENTAL
Intervention: Chymotrypsin-galactose pretreatment before IUI
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional IUI (Control)
Number of subjects: 26
Study: 8338943

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX), 1,600 mg/d in four divided doses from day -8 until day +100 post-BMT
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control (no PTX)
Number of subjects: 140
Study: 3520988

Group type: EXPERIMENTAL
Intervention: OKT3 monoclonal antibody
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional treatment with azathioprine and high‐dose steroids
Number of subjects: 13
Study: 29284645

Group type: EXPERIMENTAL
Intervention: Parenting program focused on reading aloud; included borrowing children's books weekly and monthly parent workshops.
Number of subjects: 566

Group type: COMPARATOR
Intervention: Standard child care without a parenting component (control).
Number of subjects: 566
Study: 27688200

Group type: EXPERIMENTAL
Intervention: GPi DBS
Number of subjects: 128

Group type: COMPARATOR
Intervention: STN DBS
Number of subjects: 128
Study: 24990022

Group type: EXPERIMENTAL
Intervention: Metacognitive knowledge of disabilities (intellectual awareness)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Online awareness (self-prediction)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Online awareness (self-assessment)
Number of subjects: 34
Study: 21398413

Group type: EXPERIMENTAL
Intervention: Normal-tension glaucoma patients (NTG)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Controls without ON or intracranial disease
Number of subjects: 18
Study: 20012230

Group type: EXPERIMENTAL
Intervention: Autologous stem cell therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18435713

Group type: EXPERIMENTAL
Intervention: Mental imagery rehearsal technique
Number of subjects: 64

Group type: COMPARATOR
Intervention: Textbook study
Number of subjects: 64
Study: 16180148

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 41
Study: 12593055

Group type: EXPERIMENTAL
Intervention: Open technique (OT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Closed technique (CT)
Number of subjects: 50
Study: 10190763

Group type: EXPERIMENTAL
Intervention: Uribenz 300
Number of subjects: 18

Group type: COMPARATOR
Intervention: Zyloric 300
Number of subjects: 18
Study: 7498223

Group type: EXPERIMENTAL
Intervention: Planar thallium-201 perfusion and FDG metabolism imaging
Number of subjects: 27
Study: 2108113

Group type: EXPERIMENTAL
Intervention: Aminoglycosides given once daily (4.5 mg/kg bodyweight/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Aminoglycosides given three times a day (4.5 mg/kg bodyweight/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Gentamicin three times a day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gentamicin once daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nephrotoxicity across all treatment groups
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aminoglycosides once daily
Number of subjects: 60
Study: 7387817

Group type: EXPERIMENTAL
Intervention: 35 microgram i.v. naloxone
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 70 microgram i.v. naloxone
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 200 microgram i.m. naloxone
Number of subjects: 29
Study: 30716477

Group type: EXPERIMENTAL
Intervention: Genetically estimated 25(OH)D concentration increase of 20 nmol/L for BE risk
Number of subjects: 17159

Group type: EXPERIMENTAL
Intervention: Genetically estimated 25(OH)D concentration increase of 20 nmol/L for EAC risk
Number of subjects: 17159
Study: 29227571

Group type: EXPERIMENTAL
Intervention: Metformin XR
Number of subjects: 532

Group type: COMPARATOR
Intervention: Metformin IR
Number of subjects: 532
Study: 27741153

Group type: EXPERIMENTAL
Intervention: Probiotic treatment with Bifidobacterium breve BR03, B. breve B632, and Lactobacillus delbrueckii subsp. delbrueckii LDD01 at a concentration of 10 viable cells/strain/daily dose (5 drops)
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Control group of 2000 babies from the same community
Number of subjects: 4000
Study: 25172877

Group type: EXPERIMENTAL
Intervention: Automated insulin pump system
Number of subjects: 35

Group type: COMPARATOR
Intervention: Manual BG entry system
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Automated insulin pump system in adolescent subgroup
Number of subjects: 35
Study: 22965989

Group type: EXPERIMENTAL
Intervention: Warfarin plus 81 mg of aspirin (n=28)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Aspirin 325 mg only (n=28)
Number of subjects: 56
Study: 20687826

Group type: EXPERIMENTAL
Intervention: Minocycline treatment for at least 2 weeks
Number of subjects: 50
Study: 18076250

Group type: EXPERIMENTAL
Intervention: Bruce protocol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Modified Astrand protocol
Number of subjects: 30
Study: 15618332

Group type: EXPERIMENTAL
Intervention: Plyometric portion of the drop jumps
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Counter movement jump
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Jumping jacks
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Drop jump from 10 cm
Number of subjects: 70
Study: 11948829

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) preparation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Water
Number of subjects: 22
Study: 9465357

Group type: EXPERIMENTAL
Intervention: Contact group (received three brief telephone calls at 2 weeks, 2 months, and 4 months after training)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Noncontact group (did not receive reinforcement contact)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Contact group
Number of subjects: 198

Group type: COMPARATOR
Intervention: Noncontact group
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Patients identified as ready to quit smoking
Number of subjects: 198
Study: 7620843

Group type: EXPERIMENTAL
Intervention: One-group conditions (judging group alone)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Two-group conditions (judging both groups)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Two-group conditions with non-stereotypic traits
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Second experiment (N = 297) with additional manipulation of trait favourableness
Number of subjects: 65
Study: 1974071

Group type: EXPERIMENTAL
Intervention: Alpidem 25-150 mg daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lorazepam 1-6 mg daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alpidem 25 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alpidem 50 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lorazepam 2 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alpidem 100 mg
Number of subjects: 24
Study: 407056

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 7262175

Group type: EXPERIMENTAL
Intervention: Intravenous prednisolone injection at three different doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral prednisolone at five different doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both intravenous and oral administration of prednisolone
Number of subjects: 0
Study: 31365188

Group type: EXPERIMENTAL
Intervention: FDC EZE/ROS5
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual ROS tablets
Number of subjects: 0
Study: 30559162

Group type: EXPERIMENTAL
Intervention: Outpatient precision-exercise intervention group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Delayed intervention group
Number of subjects: 200
Study: 27328378

Group type: EXPERIMENTAL
Intervention: WBV warm-up
Number of subjects: 20

Group type: COMPARATOR
Intervention: no-WBV warm-up
Number of subjects: 20
Study: 26958466

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for chronic pain, 11-week duration
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Educational materials (active control)
Number of subjects: 19
Study: 22797843

Group type: EXPERIMENTAL
Intervention: Enhanced communication therapy specific to aphasia or dysarthria, offered by speech and language therapists for up to four months.
Number of subjects: 170

Group type: COMPARATOR
Intervention: Attention control (unstructured social contact) provided by employed visitors.
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Enhanced communication therapy
Number of subjects: 170

Group type: COMPARATOR
Intervention: Attention control (unstructured social contact)
Number of subjects: 170
Study: 21302487

Group type: EXPERIMENTAL
Intervention: Compound Danshen Dripping Pill (CDDP) 10 pills, thrice daily for 18 months
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Compound Danshen Dripping Pill (CDDP)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Aspirin 0.1 g, once daily for 18 months
Number of subjects: 108

Group type: COMPARATOR
Intervention: Vitamin E 0.1 g, twice daily for 18 months
Number of subjects: 108
Study: 17057393

Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 153

Group type: COMPARATOR
Intervention: Attention placebo (Control)
Number of subjects: 153
Study: 15707755

Group type: EXPERIMENTAL
Intervention: Kothala Himbutu tea for 3 months
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Kothala Himbutu tea
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 12059064

Group type: EXPERIMENTAL
Intervention: Sedation with 0.1 mg/kg of midazolam
Number of subjects: 8

Group type: COMPARATOR
Intervention: No sedation (control group)
Number of subjects: 8
Study: 10460138

Group type: EXPERIMENTAL
Intervention: Attempting to break the fall by using an arm (slap condition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Falling with the body tensed (tensed condition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Falling with the body relaxed (relaxed condition)
Number of subjects: 0
Study: 7605188

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol based bisacodyl suppositories (PGB)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Hydrogenated vegetable oil based bisacodyl suppositories (HVB)
Number of subjects: 26
Study: 2371435

Group type: EXPERIMENTAL
Intervention: 200 micrograms inhaled salbutamol
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 12 micrograms inhaled formoterol
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 24 micrograms inhaled formoterol
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 349841

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of nitrous oxide in the lower extremities as part of conservative treatment.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no nitrous oxide injection).
Number of subjects: 40
Study: 31699572

Group type: EXPERIMENTAL
Intervention: Bihemispheric tDCS combined with physical therapy (PT) and occupational therapy (OT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham bihemispheric tDCS combined with physical therapy (PT) and occupational therapy (OT)
Number of subjects: 32
Study: 29608733

Group type: EXPERIMENTAL
Intervention: Physical therapist-administered physical activity intervention including a wearable activity tracking device, individualized step goals, and face-to-face feedback
Number of subjects: 125

Group type: COMPARATOR
Intervention: Standardized physical therapy alone after TKR
Number of subjects: 125
Study: 27072443

Group type: EXPERIMENTAL
Intervention: Mixed practice module
Number of subjects: 58

Group type: COMPARATOR
Intervention: Blocked practice module
Number of subjects: 58
Study: 24058189

Group type: EXPERIMENTAL
Intervention: Acetaminophen (oral dose)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 11
Study: 23707270

Group type: EXPERIMENTAL
Intervention: Tanezumab (5 or 10mg intravenous, up to 2 doses in 8-week intervals)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Oxycodone (10 to 40 mg every 12 hours)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610
Study: 20433721

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation with polyethylene glycol (Group A)
Number of subjects: 244

Group type: COMPARATOR
Intervention: No mechanical bowel preparation (Group B)
Number of subjects: 244
Study: 18657146

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (30 mug ethinyl estradiol and 150 mug levonorgestrel) administered daily for 21 days starting on the first day of the menstrual cycle.
Number of subjects: 82

Group type: COMPARATOR
Intervention: Natural menstrual cycle (control group).
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (COC) in the first week of the cycle.
Number of subjects: 82

Group type: COMPARATOR
Intervention: Natural cycle in the first week.
Number of subjects: 82
Study: 16825272

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 157

Group type: COMPARATOR
Intervention: Travoprost 0.004%
Number of subjects: 157
Study: 12810896

Group type: EXPERIMENTAL
Intervention: Multimedia group using the interactive program to learn about home safety
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Traditional learning group reading booklets on home safety
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group receiving no instruction on safety
Number of subjects: 126
Study: 10743861

Group type: EXPERIMENTAL
Intervention: Essential oil-containing antiseptic mouthrinse (Listerine Antiseptic)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sterile water control
Number of subjects: 29
Study: 9382217

Group type: EXPERIMENTAL
Intervention: Ketanov
Number of subjects: 42

Group type: COMPARATOR
Intervention: Tramal
Number of subjects: 42
Study: 8473538

Group type: EXPERIMENTAL
Intervention: BRAUN electric toothbrush (D5)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: BRAUN electric toothbrush (D3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: manual toothbrush (M)
Number of subjects: 60
Study: 3513357

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) at a dose of 30 ng/kg . min
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 15
Study: 29287664

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) in combination with Contingency Management (CM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACT+CM in combination with modafinil
Number of subjects: 0
Study: 27799387

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14